Jennison Associates
OLMA icon

Jennison Associates’s Olema Pharmaceuticals OLMA Stock Holding History

Jennison Associates’s Portfolio OLMA Stock Details OLMA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-1,822,123
Closed -$27.2M – 607
2026
Q1 		$27.2M Buy
1,822,123
+858,126
+89% +$19.1M 0.02% 292
2025
Q4 		$24.1M Buy
+963,997
New +$17.2M 0.01% 313

Other funds holding OLMA

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.68B AUM 126.09% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
LGM
Logos Global Management San Francisco, California $2.32B AUM 536.01% 1-Year Est. Return

Jennison Associates's OLMA Position: Q2 2026 in Review

Jennison Associates sold out of Olema Pharmaceuticals (OLMA) in Q2 2026, closing a stake of 1,822,123 shares — an estimated $27.2M sold.

Jennison Associates first reported a position in OLMA in Q4 2025 and held it in 2 quarters. The position peaked at $27.2M in Q1 2026. 186 funds tracked by Wall St. Rank hold OLMA as of Q2 2026.

  • Jennison Associates reported no remaining Olema Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
  • Jennison Associates sold 1,822,123 Olema Pharmaceuticals shares in Q2 2026, an estimated $27.2M.
  • Jennison Associates first reported a position in Olema Pharmaceuticals in Q4 2025 and held it in 2 quarters.
  • Jennison Associates's Olema Pharmaceuticals position peaked at $27.2M in Q1 2026.
  • 186 funds tracked by Wall St. Rank held Olema Pharmaceuticals as of Q2 2026.

Based on Jennison Associates's 13F filing for Q2 2026, filed 3 Aug 2026.